Skip to main content
. 2021 Sep 7;10(2):1497–1509. doi: 10.1007/s40122-021-00302-8

Fig. 3.

Fig. 3

a Network chart based on the average pain intensity after treatment. b Network chart based on the proportion of patients who discontinued treatment because of adverse treatment effects. *PGB pregabalin, GBP gabapentin